treatment-resistant depression Archives

What Alto Neuroscience’s ALTO-101 setback reveals about the difficulty of treating cognitive impairment in schizophrenia

By Pallavi Madhiraju on April 2, 2026 Pharma & Biotech

Alto Neuroscience’s ALTO-101 missed in Phase 2. Read what the setback means for schizophrenia cognition, partnering prospects, and ALTO-207 next.

FDA clears compact SPRY TMS system: can Soterix Medical disrupt the depression treatment market?

By Pallavi Madhiraju on March 6, 2026 Medical Devices & Diagnostics

Soterix Medical wins FDA clearance for SPRY TMS in treatment-resistant major depression. What the clearance means for the neuromodulation market. Read the analysis.

Why Compass Pathways’ upcoming COMP360 data could redefine late-stage psychedelic drug development

By Pallavi Madhiraju on February 17, 2026 Pharma & Biotech

Compass Pathways is set to release pivotal Phase 3 COMP360 data in treatment-resistant depression. Find out why this readout could reshape psychedelic drug development.